228 related articles for article (PubMed ID: 27913492)
1. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
Fowler N
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):277-283. PubMed ID: 27913492
[TBL] [Abstract][Full Text] [Related]
2. Novel agents for relapsed and refractory follicular lymphoma.
Cheah CY; Fowler NH
Best Pract Res Clin Haematol; 2018 Mar; 31(1):41-48. PubMed ID: 29452665
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
4. Management options for follicular lymphoma: observe; R-CHOP; B-R; others?
McLaughlin P
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S91-5. PubMed ID: 22035757
[TBL] [Abstract][Full Text] [Related]
5. Follicular lymphoma: evolving therapeutic strategies.
Kahl BS; Yang DT
Blood; 2016 Apr; 127(17):2055-63. PubMed ID: 26989204
[TBL] [Abstract][Full Text] [Related]
6. One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?
Roschewski M; Hill BT
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():467-476. PubMed ID: 31099693
[TBL] [Abstract][Full Text] [Related]
7. High-risk follicular lymphoma: Treatment options.
Kahl B
Hematol Oncol; 2021 Jun; 39 Suppl 1():94-99. PubMed ID: 34105813
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interferon-alpha therapy in patients with follicular lymphoma.
Ozer H; Wiernik PH; Giles F; Tendler C
Cancer; 1998 May; 82(10):1821-30. PubMed ID: 9587113
[TBL] [Abstract][Full Text] [Related]
9. Use of rituximab in patients with follicular lymphoma.
Marcus R
Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):38-49. PubMed ID: 17305253
[TBL] [Abstract][Full Text] [Related]
10. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.
Procházka V; Papajík T; Janíková A; Belada D; Kozák T; Šálek D; Sýkorová A; Móciková H; Campr V; Dlouhá J; Langová K; Fürst T; Trněný M
Leuk Lymphoma; 2017 Mar; 58(3):601-613. PubMed ID: 27666539
[TBL] [Abstract][Full Text] [Related]
11. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
12. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States.
Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Taylor M; Friedberg JW; Koff JL; Link BK; Cerhan JR; Dawson KL; Flowers CR
Leuk Lymphoma; 2015 May; 56(5):1295-302. PubMed ID: 25263322
[TBL] [Abstract][Full Text] [Related]
14. Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.
Junlén HR; Lockmer S; Kimby E; Wahlin BE
Ann Hematol; 2020 Oct; 99(10):2357-2366. PubMed ID: 32808106
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
16. RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.
Lim SH; Linton KM; Collins GP; Dhondt J; Caddy J; Rossiter L; Vadher K; Fines K; Rogers LE; Fernando D; Stanton L; Davies AJ; Johnson PWM; Griffiths G
Trials; 2018 Nov; 19(1):619. PubMed ID: 30413184
[TBL] [Abstract][Full Text] [Related]
17. The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.
Mozas P; Sorigué M; Rivas-Delgado A; Rivero A; Correa JG; Castillo C; Nadeu F; Bataller A; Giné E; Baumann T; Delgado J; Villamor N; Campo E; Magnano L; Sancho JM; López-Guillermo A
Eur J Haematol; 2021 Mar; 106(3):428-432. PubMed ID: 33247499
[No Abstract] [Full Text] [Related]
18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Vidal L; Gafter-Gvili A; Gurion R; Raanani P; Dreyling M; Shpilberg O
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009045. PubMed ID: 22972131
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F; Fowler NH; Feugier P; Bouabdallah R; Tilly H; Palomba ML; Fruchart C; Libby EN; Casasnovas RO; Flinn IW; Haioun C; Maisonneuve H; Ysebaert L; Bartlett NL; Bouabdallah K; Brice P; Ribrag V; Daguindau N; Le Gouill S; Pica GM; Martin Garcia-Sancho A; López-Guillermo A; Larouche JF; Ando K; Gomes da Silva M; André M; Zachée P; Sehn LH; Tobinai K; Cartron G; Liu D; Wang J; Xerri L; Salles GA;
N Engl J Med; 2018 Sep; 379(10):934-947. PubMed ID: 30184451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
